Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank88
3Y CAGR+26.3%
5Y CAGR+31.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+26.3%/yr
vs +5.9%/yr prior
5Y CAGR
+31.7%/yr
Recent deceleration
Acceleration
+20.4pp
Accelerating
Percentile
P88
Within normal range
vs 5Y Ago
4x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $84.77M | +120.1% |
| 2024 | $38.51M | -66.1% |
| 2023 | $113.47M | +169.4% |
| 2022 | $42.12M | +38.0% |
| 2021 | $30.52M | +42.7% |
| 2020 | $21.39M | -62.2% |
| 2019 | $56.57M | +68.9% |
| 2018 | $33.50M | +45.7% |
| 2017 | $22.99M | - |